Home > Healthcare & Medical Devices > Spine Biologics Market

Spine Biologics Market Size - By Product [Bone Graft (Allograft, Autograft), Bone Graft Substitutes (Demineralized Bone Matrix, Synthetic Bone Graft), Platelet Rich Plasma], Surgery (ACDF, PLIF, TLIF), By End-use - Global Forecast to 2032

  • Report ID: GMI6096
  • Published Date: Jun 2023
  • Report Format: PDF

Spine Biologics Industry Analysis 

Spine Biologics Market size in 2022 was valued at USD 2.2 billion in 2022 and is expected to witness CAGR of 4.3% by 2032 owing to increasing prevalence of spine deformities, growing awareness and patient preference for minimally invasive procedures, and technological advancements.

Spine Biologics Market

To get more details on this report: Request Free Sample PDF

Spine biologics refer to a type of medical treatments or therapies that are developed by using biological materials or substances for treating various spinal conditions and disorders. They are used as alternatives to traditional surgical techniques, and provide biological support by promoting bone healing, fusion, and regeneration of the spine. They facilitate in reducing pain, improve functioning and better quality of life.

COVID-19 Impact

The COVID-19 pandemic has had a significant impact on the spine biologics market. During the pandemic, due to the implementation of lockdown and travel restrictions, many elective surgeries, including spinal procedures, were either postponed or cancelled in order to reduce the risk of infection. It reduced the number of spine surgeries performed and a temporary decline in the demand for spine biologics. The pandemic caused disruption in the global supply chain, leading to a decrease in the production and distribution of spine biologics. Manufacturing facilities experienced challenges in maintaining normal operations, affecting production, which led to potential shortages or delays in the availability of spine biologic products.

With the vaccination efforts and infection control measures implemented to reduce the risk of infection, elective surgeries, including spine procedures. The backlog of postponed surgeries has created an increasing demand, leading to the recovery of the utilization of spine biologics. The pandemic has brought attention to the benefits of minimally invasive procedures, such as smaller incisions, fewer hospitalizations, and rapid recovery times. Spine biologics used in conjunction with minimally invasive techniques are expected to increase in demand due to the growing awareness and patient preference for such approaches.

Spine Biologics Market Driving Factors 

The increasing prevalence of spinal disorders, rising geriatric population, growing demand for minimally invasive procedures are the major factors contributing to the overall expansion of this market. The geriatric population is more likely to develop spinal disorders such as degenerative disc disease, spinal stenosis, and osteoporosis-related fractures. Such conditions often need surgical intervention which involves utilization of spine biologics. The growing geriatric population, thus result in increased demand for spine surgeries associated with biologics. The surgical techniques and technologies have advanced with the time, that makes spine surgeries safer and more effective treatment option for such patients. The utilization of spine biologics helps in improving the fusion process, surgical outcomes, and minimize risk associated with spine surgeries in geriatric patients.

Spine Biologics Product Segmentation  

Spine Biologics Market Size, By Product,

To get more details on this report: Request Free Sample PDF

Based on products, the spine biologics market is segmented into bone grafts, bone graft substitutes, platelet-rich plasma, bone marrow aspirate therapy, and other products. The bone graft segment is further sub-segmented into allografts and autografts. The bone graft substitute segment is further sub-segmented into demineralized bone matrix, synthetic bone grafts, and bone morphogenetic proteins. The bone graft substitutes segment accounted for the largest market share of 64.1% in 2022. In addition to this, it reduces the risk associated with the disease transmission, has osteoconductive properties, osteoinductive potential, and offers the structural integrity and stability.

Spine Biologics Surgery Type Segmentation 

Based on surgery type, the spine biologics market is classified into anterior cervical discectomy and fusion, posterior lumbar interbody fusion, transforaminal lumbar interbody fusion, anterior lumbar interbody fusion, lateral lumbar interbody fusion, and other surgery types. The anterior cervical discectomy and fusion segment was valued at USD 834.9 million in 2022. It is an effective treatment option for relieving pain caused by cervical disc disease. Most patients experience significant pain relief immediately after this surgery. They also help improve the functioning and movement of arms and hands.

Spine Biologics End-User Segmentation 

Spine Biologics Market Share, By End-user

To get more details on this report: Request Free Sample PDF

Based on end-user, the spine biologics market is sub-divided into hospitals, ambulatory surgical centres, and other end-users. Hospitals segment is expected grow at CAGR of 4.1% by 2032. The hospitals are equipped with comprehensive healthcare facilities, including specialized departments and multidisciplinary teams that can provide a full range of spine care services. This includes diagnostics, surgical interventions, and post-operative care, making hospitals an attractive choice for patients requiring spine biologics. In addition to this, the hospitals typically have established relationships with insurance providers and can facilitate insurance coverage and reimbursement processes for patients undergoing spine biologics procedures. This industry it easier for patients to access and afford these treatments.

Spine Biologics Regional Analysis  

U.S. Spine Biologics Market Size,

Based on the region, North America spine biologics market is expected to reach USD 1.4 billion by 2032. The region has a relatively high prevalence of spinal conditions, such as degenerative disc disease, spinal stenosis, and spinal deformities. This results in a significant patient pool for surgical interventions, such as the use of spine biologics. In addition to this, North America has a well-developed healthcare system, presence of prominent players in this business, and increased awareness and demand for minimally invasive procedures.

Spine Biologics Industry Leaders 

The key players in the spine biologics market are Zimmer Biomet Holdings, Inc., Johnson and Johnson (Depuy Synthes), Orthofix Medical Inc., Stryker Corporation, Arthrex, Inc., Medtronic, Inc., K2M, Inc., Exactech, Inc., Wright Medical Technology, Inc., and Nuvasive, Inc.

Spine Biologics Industry News:

  • In February 2022, Orthofix Medical Inc. announced the market launch of Opus BA, a synthetic bioactive bone graft solution for cervical and lumbar spine fusion procedures. This helped company to boost the revenue and reach untapped markets.
  • In April 2023, Bone Biologics received Human Research Ethics Committee approval to begin pilot clinical trial with NB1 bone graft in spinal fusion patients in Australia. It has significantly impacted the research and development of the product and also helped the company to expand their product portfolio.

The spine biologics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Product

  • Bone grafts
    • Allografts
    • Autografts
  • Bone graft substitutes
    • Demineralized bone matrix
    • Synthetic bone grafts
    • Bone morphogenetic proteins
  • Platelet-rich plasma
  • Bone marrow aspirate therapy
  • Other products

By Surgery Type

  • Anterior cervical discectomy and fusion (ACDF)
  • Posterior lumbar interbody fusion (PLIF)
  • Transforaminal lumbar interbody fusion (TLIF)
  • Anterior lumbar interbody fusion (ALIF)
  • Lateral lumbar interbody fusion (LLIF)
  • Other surgery types

By End-user

  • Hospital
  • Ambulatory surgical centers
  • Other end-users

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Switzerland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Rest of Middle East & Africa


Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Spine biologics industry share had reached USD 2.2 billion in 2022 and is estimated to witness 4.3% CAGR from 2023-2032 due to the rapidly expanding geriatric population and high burden of spine deformities worldwide

The bone graft substitutes product segment held 64.1% of the market share in 2022 driven by their ease of accessibility

The hospitals end-use segment is expected to record 4.1% CAGR from 2023-2032 owing to the robust presence of comprehensive healthcare facilities, including specialized departments and multidisciplinary teams

North America industry size may reach USD 1,409.2 million by 2032 due to the high prevalence of spinal conditions, such as degenerative disc disease, spinal stenosis, and spinal deformities in the region

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Premium Report Details

  • Base Year: 2022
  • Companies covered: 10
  • Tables & Figures: 340
  • Countries covered: 22
  • Pages: 195
Inquiry Before Buying

Budget constraints? Get in touch with us for special pricing

Request Discount